Vivos Therapeutics, Inc. 8-K

What Happened
Vivos Therapeutics, Inc. (VVOS) reported in an 8‑K (filed April 22, 2026) that Nasdaq’s Listing Qualifications Staff sent a letter on April 17, 2026 notifying the company that its stockholders’ equity reported in its Form 10‑K for the year ended December 31, 2025 did not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The Form 10‑K showed negative stockholders’ equity of approximately $1.55 million as of December 31, 2025.

Key Details

• Deficiency: Reported negative stockholders’ equity of ~$(1.55) million as of 12/31/2025 vs. Nasdaq minimum of $2,500,000.
• Nasdaq timeline: Company has 45 calendar days (until June 1, 2026) to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days total (through October 14, 2026) to regain compliance.
• Recent financings: In Q1 2026 the company raised aggregate gross proceeds of $6.8 million: $4.6 million from a warrant exercise inducement and $2.25 million from a private placement with an existing investor.
• Next steps: If Nasdaq rejects the plan or the company fails to regain compliance, Nasdaq would issue a delisting determination; the company could request a hearing, which would stay delisting while the matter is considered.

Why It Matters
This notice signals that Vivos currently does not meet Nasdaq’s minimum equity standard, which could lead to delisting if the company cannot convince Nasdaq it will regain compliance. The recent $6.8M financings improve the company’s capital position but do not automatically cure the deficiency; successful remedy depends on Nasdaq accepting the company’s plan and the company demonstrating compliance within any granted extension. Delisting from Nasdaq would likely have a materially adverse effect on liquidity, investor perception, and the company’s ability to raise capital.